IRIS
GIULIANO, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.152
NA - Nord America 5.216
EU - Europa 4.070
SA - Sud America 686
Continente sconosciuto - Info sul continente non disponibili 281
AF - Africa 132
OC - Oceania 8
Totale 16.545
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.962
SG - Singapore 2.606
RU - Federazione Russa 1.819
CN - Cina 1.248
VN - Vietnam 1.123
IT - Italia 1.088
BR - Brasile 532
HK - Hong Kong 441
DE - Germania 264
FR - Francia 197
NL - Olanda 158
BD - Bangladesh 147
IN - India 144
CA - Canada 138
GB - Regno Unito 118
FI - Finlandia 108
JP - Giappone 98
KR - Corea 76
AR - Argentina 68
IE - Irlanda 58
MX - Messico 54
SE - Svezia 44
CI - Costa d'Avorio 42
PL - Polonia 36
UA - Ucraina 34
ZA - Sudafrica 34
IQ - Iraq 32
ES - Italia 30
PH - Filippine 30
TH - Thailandia 29
PK - Pakistan 28
AT - Austria 23
EC - Ecuador 22
BE - Belgio 20
CO - Colombia 16
VE - Venezuela 16
TR - Turchia 15
ID - Indonesia 14
JM - Giamaica 14
TW - Taiwan 14
MY - Malesia 12
UZ - Uzbekistan 12
MA - Marocco 11
NP - Nepal 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
EG - Egitto 9
LT - Lituania 9
PY - Paraguay 9
CL - Cile 8
RS - Serbia 8
SA - Arabia Saudita 8
JO - Giordania 7
CR - Costa Rica 6
DZ - Algeria 6
HN - Honduras 6
PE - Perù 6
PS - Palestinian Territory 6
AU - Australia 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
IR - Iran 5
KE - Kenya 5
LB - Libano 5
MD - Moldavia 5
UY - Uruguay 5
BS - Bahamas 4
BY - Bielorussia 4
IL - Israele 4
KZ - Kazakistan 4
LV - Lettonia 4
MN - Mongolia 4
PT - Portogallo 4
SY - Repubblica araba siriana 4
TN - Tunisia 4
AL - Albania 3
BB - Barbados 3
BG - Bulgaria 3
BW - Botswana 3
BZ - Belize 3
CH - Svizzera 3
DK - Danimarca 3
ET - Etiopia 3
HR - Croazia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PA - Panama 3
PR - Porto Rico 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AZ - Azerbaigian 2
BF - Burkina Faso 2
BO - Bolivia 2
GE - Georgia 2
GR - Grecia 2
IS - Islanda 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
Totale 16.232
Salva come PNG Salva come JPEG
Città #
Singapore 1.280
San Jose 893
Moscow 453
Ashburn 441
Chandler 427
Hong Kong 426
Beijing 362
Hefei 349
Ho Chi Minh City 303
Hanoi 252
Naples 231
Santa Clara 221
Los Angeles 133
The Dalles 131
Dallas 130
Amsterdam 128
Napoli 121
Lauterbourg 116
Millbury 113
New York 98
Munich 93
Tokyo 83
Buffalo 79
Council Bluffs 68
Milan 59
Seoul 57
Kochi 54
Princeton 54
Haiphong 53
São Paulo 53
Des Moines 51
Rome 50
Redondo Beach 49
Da Nang 48
Nanjing 44
Turku 43
Orem 41
Boston 40
Wilmington 38
Dong Ket 36
Montreal 36
Toronto 36
Lawrence 35
Frankfurt am Main 33
Seattle 30
Pune 28
Warsaw 28
Ottawa 27
Mexico City 26
Nuremberg 26
Brooklyn 24
Houston 24
Denver 22
Jacksonville 22
Atlanta 21
London 21
Stockholm 20
Poplar 19
Rio de Janeiro 19
Chicago 18
Biên Hòa 17
Hải Dương 17
Belo Horizonte 15
Johannesburg 15
Lappeenranta 15
Boardman 14
Shanghai 14
Casoria 13
Formia 13
Ninh Bình 13
Pomigliano d'Arco 13
Tianjin 13
Bangkok 12
Brussels 12
Charlotte 12
Chennai 12
Helsinki 12
Kingston 12
Nanchang 12
Vienna 12
Baghdad 11
Dearborn 11
Manchester 11
Phoenix 11
Tashkent 11
Washington 11
Woodbridge 11
Bologna 10
Can Tho 10
Falkenstein 10
Porto Alegre 10
Shenyang 10
Thái Nguyên 10
Changsha 9
Guayaquil 9
Miami 9
Villaricca 9
Caserta 8
Curitiba 8
Dublin 8
Totale 8.681
Salva come PNG Salva come JPEG
Nome #
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 207
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 202
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 195
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 193
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 186
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 183
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 182
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 181
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 180
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients 179
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 174
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 169
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 167
Prevalence of Sarcopenia in Women with Breast Cancer 163
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 162
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 162
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 161
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations 160
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) 159
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 157
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 156
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 156
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 155
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 155
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 153
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 152
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 152
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 150
Tumor characteristics and prognosis in familial breast cancer 149
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 149
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 148
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 147
Mechanisms of lapatinib resistance in HER2-driven breast cancer 147
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 147
A djuvant treatment in patients at high risk of recurrence of thymoma: Efficacy and safety of a three-dimensional conformal radiation therapy regimen 146
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 146
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 145
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 145
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 144
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 144
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 143
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 142
R0 surgical resection of giant dedifferentiated retroperitoneal liposarcomas in the COVID era with and without nephrectomy: A case report 141
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions 141
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 140
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. 138
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 138
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 136
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 136
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 135
Boosting the immune response with the combination of electrochemotherapy and immunotherapy: A new weapon for squamous cell carcinoma of the head and neck? 135
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 133
Tumori maligni del colon 133
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 133
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy 133
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 131
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 130
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 130
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 130
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase 129
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 127
Epigenetic control of gene expression: Potential implications for cancer treatment 127
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 126
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 126
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 126
Crosslink between atrial fibrillation and cancer: a therapeutic conundrum 124
Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors 123
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 122
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 121
Circulating tumor cells in newly diagnosed inflammatory breast cancer 121
Immunological signature of patients with thymic epithelial tumors and Good syndrome 120
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 119
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. 118
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 118
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. 118
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 117
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 116
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. 116
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 115
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 115
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. 114
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study 113
Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes 113
Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report 113
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 112
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. 112
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 112
Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response 112
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 111
Cardio-Oncology Challenges in Elderly Patients 110
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis 110
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 110
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 109
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 109
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome 107
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 105
Genetics and management of locally advanced carcinomas of the head and neck: Role of altered fractionation radiotherapy 105
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 104
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. 100
Totale 13.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.697
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022587 0 4 17 9 6 24 14 23 67 60 154 209
2022/20231.004 96 89 37 64 128 104 18 95 146 150 53 24
2023/2024786 33 120 96 51 42 102 11 75 23 24 130 79
2024/20254.196 167 174 14 104 125 224 416 241 350 483 1.562 336
2025/20268.624 891 666 962 832 1.343 404 945 457 929 629 234 332
2026/2027364 261 103 0 0 0 0 0 0 0 0 0 0
Totale 16.545